Sonograms Enable Looking Forward - Home Examinations Led by Providers Validation Study

Fertility Risk Clinical Trial

— SELF-HELP  

Official title:

SELF-HELP Validation Study: Sonograms Enable Looking Forward - Home Examinations Led by Providers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04687189
• Other study ID #: 008
• Status: Completed
• Phase: N/A
• Start date: February 27, 2021
• Est. completion date: April 30, 2021

Study information

• Verified date: May 2021
• Source: Turtle Health, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To demonstrate that clear, interpretable quality images of the ovaries and uterus can be generated using a portable transvaginal ultrasound scanner in the home environment, and that those images are interpretable by physicians with sufficient clarity to estimate approximate antral follicle count (i.e., appropriate for age) and to observe submucosal fibroids. Study aims to prove that images taken when ultrasound is performed by a woman herself (with HCP supervision via telemedicine) and images taken when ultrasound is administered by an HCP are of comparable quality. Study population reflects real-world patient characteristics and includes both general-population and submucosal fibroid positive controls.

Description:

Today, pro-fertility information is generally unavailable to healthy women; clinically meaningful in-clinic testing is limited by physician availability and patient willingness to undergo testing in-clinic, while home testing is limited to hormonal bloodwork which is insufficient on its own and has high false positives. Sponsor is developing home telemedicine transvaginal ultrasound as part of a home fertility assessment. Sponsor wishes to demonstrate the ability to obtain interpretable images, in women of varying body habitus, reproductive age, and reproductive status.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: April 30, 2021
• Est. primary completion date: April 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 38 Years

Eligibility

Inclusion Criteria:

• Women between the ages of 18 and 38 inclusive

• Women with BMI up to 40

• Women able to freely give consent electronically, given COVID. For the purposes of this study, this is defined as women who speak native or fluent English; and have a high school degree or equivalent, and who are otherwise, in the professional judgement of the PI, able to give informed consent

• N = 30 will be recruited from the general population, e.g., no known previous issues

• N = 15 will be positive controls with submucosal fibroids

• Women who are in driving distance from Boston (including Vermont and Connecticut); these states are covered by the PI's medical license during the COVID emergency

• Women between cycle days 3 and 10 at the time of testing; or IUD users who do not have a menses

Exclusion Criteria:

• Women with expert ultrasound experience, e.g., ultrasound technologists, radiologists, OB/GYNs, Reproductive Endocrinologists

• Women with BMI over 40

• Women who do not speak English natively or fluently

• Women who have recently given birth, and have had fewer than 3 postpartum menstrual cycles

• Women who have recently had a stillbirth or abortion more than 20 weeks (subject to the 3 postpartum menstrual cycles above). Miscarriages or abortions less than 20 weeks are subject to two wait cycles

• Women who are currently pregnant or may be pregnant

• Any woman the PI believes is not capable of giving independent, informed consent

• Turtle Health employees

Related Conditions & MeSH terms

• Fertility Risk

Intervention

Device:
• Transvaginal ultrasound performed by a woman herself (with HCP supervision via telemedicine)
Imaging performed by woman on herself with remote healthcare professional (HCP) supervision compared to images taken when same ultrasound is administered in person by HCP. The ultrasound device used is cleared for HCP-supervised use in environments where healthcare is provided by trained HCPs. No changes to the design or manufacture have been made for this study.

Locations

Country	Name	City	State
United States	Virtual metasite	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Turtle Health, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinically comparable video quality of supervised self-performed scan	As assessed by two experienced, qualified independent raters on a 4 point scale for each organ visualized and each modality (supervised versus HCP). 4 point scale consists of: 4=excellent image quality; 3=acceptable image quality; 2=below clinical quality; 1=nondiagnostic. Scale is translated into binary outcome to assess if image is clinically comparable. 'Clinical-quality image' of an organ requires a score of '3' or greater on the scale.	Day 1 (self-performed scan)
Primary	Clinically comparable video quality of HCP-performed scan	As assessed by two experienced, qualified independent raters on a 4 point scale for each organ visualized and each modality (supervised versus HCP). 4 point scale consists of: 4=excellent image quality; 3=acceptable image quality; 2=below clinical quality; 1=nondiagnostic. Scale is translated into binary outcome to assess if image is clinically comparable. 'Clinical-quality image' of an organ requires a score of '3' or greater on the scale.	Day 2 (HCP-performed scan)
Secondary	Change in net promoter score (NPS) between supervised self-performed and HCP-performed scans	Evaluated by survey post ultrasound administration. Calculated as a standard NPS: 9/10 scores = 1; 7/8 scores = 0; 0-6 scores = -1, missing = 0.	Day 1 (self-performed scan) and Day 2 (HCP-performed scan)
Secondary	Change in antral follicle count (AFC) between supervised self-performed and HCP-performed scans	Difference between antral follicle count (AFC) identified in both ovaries among exams in two modalities (supervised self-performed and HCP-performed), conducted proximately (within 24-48 hours of each other)	Day 1 (self-performed scan) and Day 2 (HCP-performed scan)
Secondary	Change in detection accuracy for major submucosal fibroids between supervised self-performed and HCP-performed scans in the known history of submucosal fibroids arm	Difference between accurate identification of submucosal fibroids among exams in two modalities (supervised self-performed and HCP-performed), conducted proximately (within 24-48 hours of each other)	Day 1 (self-performed scan) and Day 2 (HCP-performed scan)
Secondary	Change in all-cause false positive rate between supervised self-performed and HCP-performed scans in the general population arm	Difference between false positive rate among exams in two modalities (supervised self-performed and HCP-performed), conducted proximately (within 24-48 hours of each other). An all-cause false positive will be defined as a subject where pathology requiring in-person follow-up is identified on the supervised self-performed exam, but not substantiated by identification by the HCP-administered exam.	Day 1 (self-performed scan) and Day 2 (HCP-performed scan)